𝛼SK or Search

ENTITY

Shanghai Henlius Biotech (2696 HK)

367

Analysis

Health Care • China

Shanghai Henlius Biotech is a global, innovation-driven biopharmaceutical company focused on delivering high-quality, affordable biologic therapies for oncology, autoimmune diseases, and ophthalmic diseases. The company is engaged in biopharmaceutical research and development, manufacturing, and commercialization, offering products such as the biosimilars HANLIKANG (rituximab), HANQUYOU (trastuzumab), HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), as well as the innovative biologic HANSIZHUANG (serplulimab). Headquartered in Shanghai, China, the company was founded in 2010.

more

Refresh

Exchange Announcement • 30 Sep 2026 17:13

List Of Directors And Their Roles And Functions

Exchange Announcement • 30 Sep 2026 17:10

(1) Changes In Non-Executive Director And Independent Non-Executive Director (2) Appointment Of Chairman Of The Board And Changes In Composition Of The Board Committees

Exchange Announcement • 24 Sep 2026 16:53

Interim Report 2026

Exchange Announcement • 23 Sep 2026 16:58

Voluntary Announcement - Collaboration And License Agreement With Amberstone For Two T Cell Engager Products

Exchange Announcement • 11 Sep 2026 16:30

Voluntary Announcement - New Drug Application (Nda) For 120 Mg (1.7 Ml) Per Vial Strength Of Biosimilar Of Denosumab Hlx14 (Recombinant Anti-Rankl Human Monoclonal Antibody Injection) Has Been Accepted By The National Medical Products Administration (Nmpa)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x